Denali Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Denali Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Denali Therapeutics: 12 sponsored US clinical trials, 3 recruiting.
Denali Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mucopolysaccharidosis II, with 2 trials.
Top-decile sponsor footprint
Denali Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
12 total, page 1 of 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
NCT07354724
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
NCT04251026
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
NCT06281158
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
NCT05006352
A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
NCT04007536
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
NCT03757325
Study to Evaluate DNL201 in Subjects With Parkinson's Disease
NCT03710707
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers
NCT04551534
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Denali Therapeutics pipeline
3 recruiting of 12 indexed (25% open); 6 completed (50%).
Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Mucopolysaccharidosis II (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Denali Therapeutics: open-pipeline peers nationwide
Peers matched on 12 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Denali Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
Related
What to do with this Denali Therapeutics page
12 registered trials is a research-attention snapshot, not an endorsement of Denali Therapeutics or any single study.
- 3 of Denali Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Mucopolysaccharidosis II is the condition Denali Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mucopolysaccharidosis II trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Denali Therapeutics pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.